RareCyte will use the SOPHiA DDM™ Platform to
support its oncology testing panel
BOSTON and ROLLE, Switzerland, Jan. 18,
2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company and a leader in data-driven
medicine, today announced that RareCyte Inc., a precision
biology company based in Seattle,
Washington, is live on SOPHiA GENETICS. RareCyte has
implemented the SOPHiA DDM™ Platform to complement its
Precision Biology Services portfolio.
RareCyte is an innovative precision biology company that
develops technologies and end-to-end integrated platforms to
support the advancement of oncology, immuno-oncology,
maternal-fetal health, and cell and gene therapy. The company will
use SOPHiA GENETICS to provide DNA sequencing of circulating tumor
cells and cell-free DNA for testing of cancer patients.
"Our team is passionate about increasing the use of precision
medicine around the world, and we are pleased to be working with
RareCyte, a company that is passionate about that as well," said
John Carey, Managing Director,
NORAM, SOPHiA GENETICS. "The pairing of our SOPHiA DDM™ Platform
with RareCyte's existing advanced solutions will enhance its
offerings, specifically with Liquid Biopsy testing, and further
RareCyte's Precision Biology Services portfolio."
The SOPHiA DDM™ Platform is a next-generation-sequencing
(NGS)-based application that uses artificial intelligence (AI) to
efficiently analyze and interpret raw NGS data for researchers.
SOPHiA GENETICS technology supports better and faster data-driven
decision-making for researchers by providing consistent and
accurate interpretation of clinically significant biomarkers.
By integrating the SOPHiA DDM™ Platform for bioinformatics
support, RareCyte will enhance their workflow with dedicated
filtering features and a rich knowledge base to identify variants
of interest to provide researchers with highly
accurate analytics and insights within hours.
With the SOPHiA DDM™ Platform, RareCyte will retain ownership of
its complete database and will have access to reproducible data to
help accelerate clinical studies in the oncology space. The SOPHiA
GENETICS technology will help RareCyte's team of scientists and
engineers as they continue to develop next-generation products and
services that advance precision medicine and biomedical
research.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect on X,
LinkedIn, Facebook, and Instagram.
For more information about RareCyte, Inc., visit rarecyte.com,
or connect on X and LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-enhances-rarecyte-precision-biology-services-portfolio-302038787.html
SOURCE SOPHiA GENETICS